Health Condition 1: C419- Malignant neoplasm of bone and articular cartilage, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Intervention5: Nil: Nil
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Histologically confirmed Ewing sarcoma of bone or soft tissue Treated with definitive radiotherapy to the primary tumor with curative intent Treatment received at TMH or ACTREC between 2000 and 2023 Minimum 6 months follow-up data available
Exclusion criteria
Exclusion criteria: Patients receiving palliative radiotherapy only Incomplete treatment or missing follow-up data after radiotherapy Patients with relapsed disease before definitive radiotherapy Patients with syndromic cancer predisposition or concurrent malignancies affecting outcome analysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-Free Survival EFS following definitive radiotherapy in Ewing s sarcoma. EFS is defined as the time from initial definitive treatment end of primary therapy to the occurrence of any failure event tumor relapse or progression or death from any cause. The primary aim of the study is to identify significant prognostic factors associated with postRT EFS and to integrate them into a multivariable prognostic nomogram for relapse riskTimepoint: Event-Free Survival EFS following definitive radiotherapy in Ewing s From completion of definitive radiotherapy up to 5 years (primary analysis at 3 years) | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control LC,Overall Survival OS and patterns of failure in this cohort. Local control will be measured from the time from initial definitive treatment end of primary therapy to local relapse. OS will be measured from time from initial definitive treatment end of primary therapy to death or last followup censored. We will document the pattern of relapse local vs. distant, or both for each patient to facilitate subset analyses e.g. comparing outcomes for isolated local relapse vs. systemic relapse. These secondary objectives will provide additional context for the nomogram for instance, by correlating the nomogram risk score with OS, and examining local control rates.Timepoint: Local control will be measured from the time from initial definitive treatment (end of primary therapy) to local relapse. OS will be measured from time from initial definitive treatment (end of primary therapy) to death or last follow-up (censored). Overall survival at 1, 3 and 5 years. Pattern of relapse recorded during follow up up to 5 years. | — |
Countries
India
Contacts
Public ContactDr Jifmi Jose Manjali
Tata Memorial Centre Parel Mumbai
Outcome results
None listed